Cortisol reduction: In a double-blind, placebo-controlled study, participants taking 600mg KSM-66 daily showed a 27.9% reduction in serum cortisol after 60 days — compared to 7.9% in the placebo group. The difference was statistically significant.
Menopausal symptoms: A separate trial in menopausal women found KSM-66 significantly reduced menopausal symptom scores on validated scales. Notably, the treatment group also showed a statistically significant increase in estradiol levels compared to placebo — making this one of the only non-hormonal interventions with evidence of influencing estrogen levels directly.
Safety: A 12-month observational study found no adverse effects on hepatic, renal, or thyroid function at clinical doses.